オカザキ　トモコ   Tomoko Okazaki   岡崎　知子    所属   川崎医科大学  医学部 臨床医学　脳卒中医学    職種   期限付講師
論文種別	症例報告
言語種別	英語
査読の有無	査読あり
表題	Lambert-Eaton Myasthenic Syndrome Caused by Nivolumab in a Patient with Squamous Cell Lung Cancer.
掲載誌名	正式名：Case reports in neurology 略　 称：Case Rep Neurol ISSNコード：1662680X/1662680X
掲載区分	国内
巻・号・頁	10(3),pp.346-352
著者・共著者	Yuki Nakatani, Natsuki Tanaka, Tomomi Enami, Seigo Minami, Tomoko Okazaki, Kiyoshi Komuta
発行年月	2018
概要	Lambert-Eaton myasthenic syndrome (LEMS) is a representative paraneoplastic neurological syndrome. Recently, nivolumab, an anti-programmed cell death 1 inhibitor, has been approved for advanced non-small-cell lung cancer. Careful attention should be paid to immune-related adverse events (irAEs), including neurotoxicity. We herein report a 73-year-old woman with LEMS that occurred during nivolumab treatment for pulmonary squamous cell carcinoma. After the 20th week of nivolumab, she experienced various neurological symptoms such as ptosis, lower limb weakness, and photophobia. Findings from a nerve conduction study and a positive anti-P/Q-type voltage-gated calcium channel antibody made a diagnosis of LEMS. Pyridostigmine and 3,4-diaminopyridine temporarily improved her symptoms. This was the first case of LEMS as a neurological irAE. LEMS should be considered as a possible neurological irAE.
DOI	10.1159/000494078
PMID	30627102